Abstract
Introduction School closures have been part of the SARS-CoV-2 pandemic control measures in many countries, based on the assumption that children play a similar role in transmitting SARS-CoV-2 as they do in transmitting influenza virus. The contribution of schools in driving the pandemic, however, is still unclear. We therefore performed a SARS-CoV-2 seroprevalence study in students and teachers at two time points in June and October 2020, respectively.
Methods Students grade 8–11 and their teachers in 13 secondary schools in eastern Saxony, Germany, were invited to participate in the SchoolCoviDD19 study. Blood samples were collected in May/June 2020 after the reopening of the schools following the March 2020 lockdown, and again in September/October 2020, 4 weeks after the end of the summer holidays. SARS-CoV-2 IgG were assed using chemiluminescence immunoassay technology and all samples with a positive or equivocal test result were retested with two additional serological tests.
Results 1538 students and 507 teachers were initially enrolled, and 1334 students and 445 teachers completed both study visits. The seroprevalence for SARS-CoV-2 antibodies was 0.6% in May/June and the same in September/October. Even in schools with reported Covid-19 cases before the lockdown of March 13th no clusters could be identified. Of 12 persons with positive serology 5 had a known history of confirmed COVID-19; 23 out of 24 participants with a household history of COVID-91 were seronegative. By using a combination of three different immunoassays we could exclude 16 participants with a positive or equivocal results after initial testing.
Conclusions Schools do not play a crucial role in driving the SARS-CoV-2 pandemic in a low prevalence setting. Transmission in families occurs very infrequently, and the number of unreported cases is low in this age group. These observations do not support school closures as a strategy fighting the pandemic in a low prevalence setting.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
DRKS00022455
Funding Statement
This study was supported by a grant from the state of Saxony
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SchoolCoviDD19 study was approved by the Ethics Committee of the Technische Universitaet (TU) Dresden (BO-EK-156042020)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article
